149 related articles for article (PubMed ID: 38532527)
1. Management of vaccinations in patients with non-Hodgkin lymphoma.
Merli M; Costantini A; Tafuri S; Bavaro DF; Minoia C; Meli E; Luminari S; Gini G
Br J Haematol; 2024 May; 204(5):1617-1634. PubMed ID: 38532527
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Perry C; Luttwak E; Balaban R; Shefer G; Morales MM; Aharon A; Tabib Y; Cohen YC; Benyamini N; Beyar-Katz O; Neaman M; Vitkon R; Keren-Khadmy N; Levin M; Herishanu Y; Avivi I
Blood Adv; 2021 Aug; 5(16):3053-3061. PubMed ID: 34387648
[TBL] [Abstract][Full Text] [Related]
4. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
Avivi I; Luttwak E; Saiag E; Halperin T; Haberman S; Sarig A; Levi S; Aharon A; Herishanu Y; Perry C
Br J Haematol; 2022 Mar; 196(6):1329-1333. PubMed ID: 35075635
[TBL] [Abstract][Full Text] [Related]
5. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccinations: The unknowns, challenges, and hopes.
Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
[TBL] [Abstract][Full Text] [Related]
7. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
[TBL] [Abstract][Full Text] [Related]
8. No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination.
Claaß LV; Mayr P; Paschold L; Weber T; Terziev D; Jehs B; Brill R; Dober J; Märkl B; Wickenhauser C; Czapiewski P; Trepel M; Claus R; Binder M
Cancer Med; 2023 Apr; 12(8):9313-9321. PubMed ID: 36775947
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment.
Tvito A; Ronson A; Ghosheh R; Kharit M; Ashkenazi J; Magen S; Broide E; Benayoun E; Rowe JM; Ofran Y; Ganzel C
Exp Hematol; 2022 Mar; 107():20-23. PubMed ID: 34952139
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
Liebers N; Speer C; Benning L; Bruch PM; Kraemer I; Meissner J; Schnitzler P; Kräusslich HG; Dreger P; Mueller-Tidow C; Poschke I; Dietrich S
Blood; 2022 Jan; 139(1):142-147. PubMed ID: 34669919
[No Abstract] [Full Text] [Related]
11. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
[No Abstract] [Full Text] [Related]
12. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
Wiedmeier-Nutor JE; Iqbal M; Rosenthal AC; Bezerra ED; Garcia-Robledo JE; Bansal R; Johnston PB; Hathcock M; Larsen JT; Bergsagel PL; Wang Y; Reeder CB; Leis JF; Fonseca R; Palmer JM; Gysbers BJ; Mwangi R; Warsame RM; Kourelis T; Hayman SR; Dingli D; Kapoor P; Kumar SK; Durani U; Villasboas JC; Paludo J; Bennani NN; Nowakowski G; Ansell SM; Castro JE; Kharfan-Dabaja MA; Lin Y; Vergidis P; Murthy HS; Munoz J
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):456-462. PubMed ID: 37003846
[TBL] [Abstract][Full Text] [Related]
13. Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.
Gundavda MK; Gundavda KK
Curr Treat Options Oncol; 2021 Sep; 22(10):95. PubMed ID: 34515857
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
[TBL] [Abstract][Full Text] [Related]
15. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Friedman MA; Curtis JR; Winthrop KL
Ann Rheum Dis; 2021 Oct; 80(10):1255-1265. PubMed ID: 34493491
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
Shapiro LC; Thakkar A; Campbell ST; Forest SK; Pradhan K; Gonzalez-Lugo JD; Quinn R; Bhagat TD; Choudhary GS; McCort M; Sica RA; Goldfinger M; Goel S; Anampa JD; Levitz D; Fromowitz A; Shah AP; Sklow C; Alfieri G; Racine A; Wolgast L; Greenberger L; Verma A; Halmos B
Cancer Cell; 2022 Jan; 40(1):3-5. PubMed ID: 34838186
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Communication Strategies for Mitigating COVID-19 Vaccine-Specific Hesitancy in Canada.
Merkley E; Loewen PJ
JAMA Netw Open; 2021 Sep; 4(9):e2126635. PubMed ID: 34591105
[TBL] [Abstract][Full Text] [Related]
18. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.
Pallett SJC; Wake R; Youngs J; Pope C; Tan NK; Taylor J; Hawkins L; Witney AA; Laing KG; Monahan IM; Akay M; Cox A; Groppelli E; Kelleher P; Miller P; Bicanic T
Br J Haematol; 2022 Mar; 196(5):1170-1174. PubMed ID: 34766331
[No Abstract] [Full Text] [Related]
[Next] [New Search]
